Related Experiment Video
Updated: May 13, 2025
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
Published on: December 20, 2024
p16, COX-2, and Ki67 Protein Expression in DCIS and Risk of Ipsilateral Invasive Breast Cancer
Thomas E Rohan1, Chenxin Zhang1, Yihong Wang2
1Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Background:
Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with the risk of subsequent ipsilateral invasive breast cancer (IBC) is limited.
Methods:
In a case-control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n = 146) and on matched subjects who did not develop IBC (controls; n = 273). Conditional logistic regression was used to estimate ORs and 95% confidence intervals for the associations between immunopositivity for p16, COX-2, and Ki67 and the risk of subsequent ipsilateral IBC.
Results:
There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, and a risk of ipsilateral IBC. Compared with all other groups, the multivariable OR (95% confidence interval) for women who were triple positive for the three markers was 1.16 (0.38-3.54).
Conclusions:
p16, COX-2, and Ki67 immunopositivity was not associated with altered risk of ipsilateral IBC in women with DCIS.
Impact:
p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.
